Compass Therapeutics, Inc.
4.50%
7,788,150
1738021
20454B104
Aug 13, 2025
Aug 18, 2025, 06:35 PM
Reporting Persons (4)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Commander Aggregator, LP | Partnership | 4.50% | 7,788,150 | 0 | 7,788,150 |
| Enavate Sciences, LP | Partnership | 4.50% | 7,788,150 | 0 | 7,788,150 |
| Enavate Sciences GP, LLC | Other | 4.50% | 7,788,150 | 0 | 7,788,150 |
| Enavate Sciences Holdings, LLC | Other | 4.50% | 7,788,150 | 0 | 7,788,150 |
Disclosure Items (2)
Common Stock, par value $0.0001 per share
Compass Therapeutics, Inc.
80 Guest St., Boston, MA, 02135
Item 5(a) of this Statement is hereby amended and restated in its entirety as follows: The information set forth in rows (11) and (13) of the cover pages of this Statement is incorporated by reference into this Item 5.
Item 5(b) of this Statement is hereby amended and restated in its entirety as follows: The information set forth in rows (11) and (13) of the cover pages of this Statement is incorporated by reference into this Item 5.
None of the Reporting Entities has effected any transactions in the Common Stock in the past 60 days.
Not Applicable
As a result of the decrease in the outstanding shares, effective as of August 14, 2025, as reported by the Issuer in the Prospectus filed on August 13, 2025, the Reporting Entities' beneficial ownership ceased to exceed 5% on such date and the Reporting Entities are no longer subject to Section 13 reporting.